Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The aim of the protocol is to study the effects of 320 mg/day of ziprasidone (Geodon) on
glucose and lipid metabolism of patients with both Diabetes Type II (DM) and schizophrenia or
schizoaffective disorder, after switching their antipsychotic medication/s from typical
and/or atypical to ziprasidone monotherapy.